Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Retirement of Dr. Sandra Horning & Appointment of Dr. Levi Garraway to Chief Medical Officer, Roche and Genentech

Dr. Sandra Horning, Chief Medical Officer and Head of Global Product Development will retire on December 31, 2019. During her decade-long tenure with Roche and Genentech, Dr. Horning brought 15 new medicines to patients and tackled some of the world’s toughest diseases including cancer, multiple sclerosis, influenza and blindness. We thank her for her incredible contributions to medicine and to the employees at our company who have been inspired and motivated by her commitment to science and patients.

Dr. Levi Garraway, who was most recently Eli Lilly’s Senior Vice President, Oncology Research & Development and Lilly Research Laboratories Novel Target Research, will succeed Dr. Horning as Chief Medical Officer and Head of Global Product Development effective October 1, 2019 and will be based in South San Francisco.

Click here to download biographies and photos.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.